Multimodality x-RAY transmission and diffraction scanner for molecular analysis of cancer specimens

Ended Project Grant Awarded Last action

Award ID
R33CA256102
Recipient
Awarding agency
Obligated
$2,161,542

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Funding
  • $1,800,607.00 Federal
  • $360,935.00 Non-federal
Place of performance
North Carolina, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Cancer research using biospecimens requires the analysis of samples with a large range of sizes (sub-MM to CM) and molecular composition over a wide range of length scales. In many cases, 3-dimensional spatial information about the specimen is critical to understanding and addressing the progression of the disease. X-RAY imaging has been widely recognized to play a key role in tissue analysis and cancer assessment. While transmission x-RAY imaging (radiography or CT) has been used successfully in some applications wherein sample morphology is highly correlated with the disease state, IT lacks molecular specificity, which limits its general utility in specimen analysis. Many groups have demonstrated the utility of x-RAY diffraction (XRD) in analyzing molecular structure in biospecimens; however, none have successfully implemented a viable method of fast and accurate 3D XRD measurement in a laboratory environment. The key challenges associated with realizing such a system include the fact that high accuracy XRD measurements have typically required access to a synchrotron or another specialized source, which is difficult for the average researcher to access. In contrast, conventional laboratory diffraction methods are slow, require destruction or alteration of the specimens, and exhibit poor or no volumetric spatial information. To overcome these challenges, we propose to develop a new radiographic imaging device that can scan the entire volume of a biospecimen and generate CO-registered, multi-modal x-RAY transmission and XRD images. Such technology would allow researchers to study molecular properties of tissue specimens with high spatial resolution and high specificity using a tool that is compact, robust, and easily accessible in an average research laboratory. The samples would be analyzed without contrast agents and with little to no sample preparation required. Through previous work, we have built, tested, and demonstrated the underlying technology required for combined transmission and diffraction imaging of biospecimens. We will now build a clinically accessible, high-resolution prototype of the scanner, test and validate its performance, and demonstrate its utility in imaging bone and breast cancer biospecimens. This project will provide a first-of-its-kind x-RAY transmission/diffraction scanner for non-destructive analysis of cancer biospecimens, which could enable pathways for new clinical studies exploring the role of XRD in tissue abnormalities, eventually leading to a better understanding of the genesis and evolution of cancer.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $262,875 $0
Amendment -$184,496 $0
Amendment $184,496 $0
Amendment $184,496 $0
Amendment -$184,496 $0
Amendment -$184,496 $0
Amendment $184,496 $0
Amendment $271,954 $0
Amendment $271,954 $0
Amendment $271,954 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $360,935 $0
Original award $360,935 $360,935
Show all 16

Quick answers

Who received award R33CA256102?

R33CA256102 was awarded to Quadridox Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2021.

How much is award R33CA256102 worth?

$2,161,542 has been obligated on R33CA256102: $1,800,607 in federal funding and $360,935 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login